Micro Aftermath Archived

Haemonetics Corporation (HAE) attend la validation du marché

Activité en déclin — le récit perd de sa pertinence.

Score 0,3

Vélocité ▲ 0,0

Articles 5

Sources 2

Plus fortes variations

Ticker	Secteur	Variation
HAE	Health Care	+20,9%

Chronologie des sentiments

Performance Sectorielle

Chronologie des événements

Aoû 09, 2026 Haemonetics Q1 Earnings Call Highlights Bullish

Aoû 07, 2026 Haemonetics Corp Q1 Sales Increase Neutral

Mai 21, 2026 Does Haemonetics (HAE) Have Enduring Growth Potential? Neutral

Mai 12, 2026 Haemonetics Q4 Earnings Call Highlights Bullish

Avr 21, 2026 Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation Neutral

Articles Liés

Haemonetics Q4 Earnings Call Highlights Yahoo Finance · Mai 12, 2026 Mixed Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation Yahoo Finance · Avr 21, 2026 Mixed

Plus fortes variations

Ticker	Secteur	Variation
HAE	Health Care	+20,9%

🤖 Aperçu AI

What happened: Haemonetics Corporation (HAE), a provider of blood management technologies, reported strong fiscal Q4 2025 results with revenue up 5% (9% organically) to $346 million and adjusted EPS of $1.29. For the full year, revenue reached $1.3 billion and adjusted EPS was $4.96. In Q1 2026, Haemonetics reported earnings of $33.01 million, or $0.72 per share, compared to $34.03 million, or $0.70 per share, last year. Riverwater Partners and Aristotle Capital Boston, LLC, both investment management companies, mentioned Haemonetics in their Q1 2026 investor letters, with Riverwater awaiting market validation for HAE.

Market impact: Haemonetics' robust performance has implications for the broader medical technology sector. The company's growth, driven by its Plasma and Blood Management Technologies, signals strength in the blood products market, which could benefit other players like Baxter International (BAX) and Terumo BCT. However, Riverwater's neutral stance suggests investors may be waiting for more market validation before fully committing to HAE's growth story.

What to watch next: Haemonetics' upcoming fiscal Q1 2026 earnings call on May 12, 2026, will provide further insight into the company's growth trajectory. Additionally, investors should keep an eye on the broader medical technology sector's performance, as any shifts in demand or regulatory changes could impact HAE's market validation narrative.

Aperçu IA au Aoû 07, 2026

Chronologie

Première observationAoû 09, 2026

Dernière mise à jourAoû 23, 2026